In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation.

@article{Kanda2005InVA,
  title={In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation.},
  author={Yoshinobu Kanda and Kumi Oshima and Yuki Asano-Mori and Koji Kandabashi and Masahiro Nakagawa and Mamiko Sakata-Yanagimoto and Koji Izutsu and Akira Hangaishi and Shiho Tsujino and Seishi Ogawa and Toru Motokura and Shigeru Chiba and Hisamaru Hirai},
  journal={Transplantation},
  year={2005},
  volume={79 10},
  pages={
          1351-7
        }
}
BACKGROUND Alemtuzumab, a humanized monoclonal antibody directed against human CD52, has a strong lympholytic effect. This study evaluates the safety of unmanipulated peripheral blood stem-cell transplantation from two or three loci-mismatched related donors using alemtuzumab in vivo. METHODS A total body irradiation-based regimen was used in young patients, whereas those 50 years or older received fludarabine-based conditioning. Alemtuzumab was added to these regimens by intravenous infusion… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

Similar Papers

Loading similar papers…